Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 1
2002 3
2003 1
2004 2
2005 5
2006 7
2007 8
2008 5
2009 6
2010 8
2011 9
2012 12
2013 5
2014 5
2015 6
2016 2
2017 4
2018 2
2019 2
2020 1
2021 2
2022 4
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

88 results

Results by year

Filters applied: . Clear all
Page 1
Upadacitinib Versus Placebo or Adalimumab in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase III, Double-Blind, Randomized Controlled Trial.
Fleischmann R, Pangan AL, Song IH, Mysler E, Bessette L, Peterfy C, Durez P, Ostor AJ, Li Y, Zhou Y, Othman AA, Genovese MC. Fleischmann R, et al. Among authors: ostor aj. Arthritis Rheumatol. 2019 Nov;71(11):1788-1800. doi: 10.1002/art.41032. Epub 2019 Aug 28. Arthritis Rheumatol. 2019. PMID: 31287230 Clinical Trial.
Upadacitinib in active ankylosing spondylitis: results of the 2-year, double-blind, placebo-controlled SELECT-AXIS 1 study and open-label extension.
van der Heijde D, Deodhar A, Maksymowych WP, Sieper J, Van den Bosch F, Kim TH, Kishimoto M, Östör AJ, Combe B, Sui Y, Duan Y, Wung PK, Song IH. van der Heijde D, et al. Among authors: ostor aj. RMD Open. 2022 Jul;8(2):e002280. doi: 10.1136/rmdopen-2022-002280. RMD Open. 2022. PMID: 35896281 Free PMC article. Clinical Trial.
The prevalence and impact of polypharmacy in rheumatology.
Lewis J, Östör AJK. Lewis J, et al. Among authors: ostor ajk. Rheumatology (Oxford). 2023 Oct 23;62(SI3):SI237-SI241. doi: 10.1093/rheumatology/kead307. Rheumatology (Oxford). 2023. PMID: 37871915 Review.
Update on biosimilars in rheumatology.
Rischin A, Östör AJ. Rischin A, et al. Among authors: ostor aj. Inflammopharmacology. 2017 Apr;25(2):177-184. doi: 10.1007/s10787-017-0333-4. Epub 2017 Mar 7. Inflammopharmacology. 2017. PMID: 28265837 Review.
Interleukin-6 and cytochrome-P450, reason for concern?
Kim S, Östör AJ, Nisar MK. Kim S, et al. Among authors: ostor aj. Rheumatol Int. 2012 Sep;32(9):2601-4. doi: 10.1007/s00296-012-2423-3. Epub 2012 Mar 27. Rheumatol Int. 2012. PMID: 22451032 Review.
Non-infectious pulmonary toxicity of rituximab: a systematic review.
Hadjinicolaou AV, Nisar MK, Parfrey H, Chilvers ER, Ostör AJ. Hadjinicolaou AV, et al. Among authors: ostor aj. Rheumatology (Oxford). 2012 Apr;51(4):653-62. doi: 10.1093/rheumatology/ker290. Epub 2011 Dec 7. Rheumatology (Oxford). 2012. PMID: 22157468 Review.
Immune checkpoint inhibitor-induced lymphocytic fasciitis.
Rischin A, Brady B, McLean C, Ostor AJK. Rischin A, et al. Among authors: ostor ajk. Intern Med J. 2018 Dec;48(12):1550-1552. doi: 10.1111/imj.14126. Intern Med J. 2018. PMID: 30517989 No abstract available.
Effect of upadacitinib on reducing pain in patients with active psoriatic arthritis or ankylosing spondylitis: post hoc analysis of three randomised clinical trials.
McInnes IB, Ostor AJK, Mease PJ, Tillett W, Baraliakos X, de Vlam K, Bessette L, Lippe R, Maniccia A, Feng D, Gao T, Zueger P, Saffore C, Kato K, Song IH, Deodhar A. McInnes IB, et al. Among authors: ostor ajk. RMD Open. 2022 Mar;8(1):e002049. doi: 10.1136/rmdopen-2021-002049. RMD Open. 2022. PMID: 35332058 Free PMC article. Clinical Trial.
88 results